



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## LG100754

Cat. No.:	HY-108523	
CAS No.:	180713-37-5	
Molecular Formula:	C <sub>26</sub> H <sub>36</sub> O <sub>3</sub>	
Molecular Weight:	396.56	
Target:	RAR/RXR	
Pathway:	Metabolic Enzyme/Protease	
Storage:	Powder	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (252.17 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass			
			1 mg	5 mg	10 mg	
			1 mM	2.5217 mL	12.6084 mL	25.2169 mL
			5 mM	0.5043 mL	2.5217 mL	5.0434 mL
10 mM	0.2522 mL	1.2608 mL	2.5217 mL			
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (6.30 mM); Clear solution; Need ultrasonic					

### BIOLOGICAL ACTIVITY

Description	LG100754 (UVI 2112) is a RXR dimers modulator. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPAR $\alpha$ and RXR:PPAR $\gamma$ heterodimers. LG100754 is an insulin sensitizer that functions through RXR <sup>[1]</sup> .	
IC <sub>50</sub> & Target	PPAR $\alpha$	PPAR $\gamma$
In Vitro	<p>LG100754 is a selective activator of endogenous RXR heterodimers<sup>[1]</sup>.</p> <p>LG100754 can also improve TNF<math>\alpha</math>-mediated insulin resistance in mature adipocytes<sup>[1]</sup>.</p> <p>LG100754 acts as a bona fide activator of endogenous RXR:PPAR<math>\gamma</math> heterodimers and regulator of insulin-dependent signaling pathways<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
In Vivo	LG100754 (100 mg/kg) completely blocks the increase in glucose levels, suggesting that LG100754 can improve insulin resistance in vivo <sup>[1]</sup> .	

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

---

[1]. Cesario RM, et al. The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol. 2001 Aug;15(8):1360-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA